Researcher

Natasha Ng is a Senior Scientist at the Stem Cells and Diabetes Lab (Adrian Teo Lab) at A*STAR IMCB. Her research work is dedicated to advancing the understanding of genetic and molecular mechanisms underlying diabetes development using stem cell technologies, and more recently to develop next generation therapies for tackling the disease. She co-founded the pre-clinical stage spinoff company, BetaLife, that is focused on stem cell therapy for regenerative medicine in diabetes. She is a recipient of multiple young researcher academic grants and has been a key player in driving several industry collaboration projects and translational efforts in the lab to derive the proof-of-concept for iPSCs for clinical applications and stem cell-derived islet cells for diabetes therapy.

Ng graduated with a BSc in Biology at Imperial College London, UK, followed by a DPhil in Medical Sciences at the University of Oxford in 2016. Her entrepreneurial journey began in 2014 when she co-founded a UK-based, early-stage medical device company, BioMe Oxford, that is developing a patented targeted gastrointestinal sampling device. The company is working in collaboration with the microbiome venture arm of US-based International Flavors & Fragrances. Aside from her work, Ng is an Adviser of Biotech Connection Singapore (BCS), after having served as President for two years and prior to that, as Consulting Lead. BCS is a non-profit that aims to promote and support entrepreneurship in life sciences and healthcare by providing a platform for academics, entrepreneurs and industry professionals to interact and build connections.